The Effect of Pre- and Postharvest Calcium Gluconate Treatments on Physicochemical Characteristics and Bioactive Compounds of Sweet Cherry during Cold Storage.

The effects of pre- and postharvest calcium gluconate (Ca-Glu) treatments on some physicochemical characteristics and bioactive compounds of sweet cherry cv. Sweetheart during cold storage were investigated. For preharvest treatments, the Ca-Glu (1%) solution was applied to the cherry trees two times at 21 and 35 days after full bloom stage. Control trees were sprayed with distilled water at the same days. Sweet cherries, sprayed with and without Ca-Glu, were dipped into cold water (4 °C) containing calcium gluconate (1%) for 30 s and only in cold water (4 °C) as control, after harvest Following each treatment, cherries were placed in plastic boxes and stored at 1 ± 0.5 °C and 90 ± 5% relative humidity for 3 weeks. The weight losses of cherries increased over time but calcium (Ca) treatments, especially pre-and postharvest combination, limited these increases compared to control groups. The best result for suppressing the respiration rate of cherries was also obtained from combined treatment. Moreover, combined treatment delayed the losses of titratable acidity, fruit firmness, decay rate and sensory quality in sweet cherries during storage comparison with the pre or postharvest application of Ca-Glu alone. The effect of Ca-Clu treatments on stem chlorophyll content and antioxidant activity was not significant. Preharvest and combined treatments retarded the loss of ascorbic acid content of cherries compared to postharvest and control treatments. The total phenolic and anthocyanin content increased regularly throughout storage, regardless of treatment; however, Ca treatments delayed the accumulation of these compounds. As a result, the combined Ca-Glu treatment could be a promising method for maintaining some physicochemical characteristics and bioactive compounds in sweet cherries during cold storage.

Calcium Chloride and Calcium Gluconate in Neonatal Parenteral Nutrition Solutions without Cysteine: Compatibility Studies Using Laser Light Obscuration Methodology.

There are no compatibility studies for neonatal parenteral nutrition solutions without cysteine containing calcium chloride or calcium gluconate using light obscuration as recommended by the United States Pharmacopeia (USP). The purpose of this study was to do compatibility testing for solutions containing calcium chloride and calcium gluconate without cysteine. Solutions of TrophAmine and Premasol (2.5% amino acids), containing calcium chloride or calcium gluconate were compounded without cysteine. Solutions were analyzed for particle counts using light obscuration. Maximum concentrations tested were 15 mmol/L of calcium and 12.5 mmol/L of phosphate. If the average particle count of three replicates exceeded USP guidelines, the solution was determined to be incompatible. This study found that 12.5 and 10 mmol/L of calcium and phosphate, respectively, are compatible in neonatal parenteral nutrition solutions compounded with 2.5% amino acids of either TrophAmine or Premasol. There did not appear to be significant differences in compatibility for solutions containing TrophAmine or Premasol when solutions were compounded with either CaCl2 or CaGlu-Pl. This study presents data in order to evaluate options for adding calcium and phosphate to neonatal parenteral nutrition solutions during shortages of calcium and cysteine.

Physical Compatibility of Calcium Chloride and Sodium Glycerophosphate in Pediatric Parenteral Nutrition Solutions.

BACKGROUND: Calcium and phosphate precipitation is an ongoing concern when compounding pediatric parenteral nutrition (PN) solutions. Considerable effort has been expended in producing graphs, tables, and equations to guide the practitioner in prescribing PN that will remain stable. Calcium gluconate is preferred over calcium chloride when compounding PN because of its superior compatibility with inorganic phosphates. PN solutions containing calcium gluconate carry a higher aluminum load than equivalent solutions compounded with calcium chloride, leading to increased potential for aluminum toxicity. This study tested the solubility of calcium chloride in PN solutions compounded with an organic phosphate component, sodium glycerophosphate (NaGP), in place of sodium phosphate. METHODS: Five PN solutions were compounded by adding calcium chloride at 10, 20, 30, 40, and 50 mEq/L and corresponding concentrations of NaGP at 10, 20, 30, 40, and 50 mmol/L. Each of the 5 solutions was compounded using 1.5% and 4% amino acids, cysteine, and lipids. The physical stability was evaluated by visual inspection (precipitation, haze, and color change). Solutions were evaluated microscopically for any microcrystals using U.S. Pharmacopeia <788> standards. RESULTS: Compatibility testing showed no changes in the PN solution in any of the concentrations tested. Calcium chloride was found to be physically compatible with NaGP in PN at the tested concentrations. CONCLUSION: Utilization of NaGP in PN solutions would eliminate the need for precipitation curves and allow for the use of calcium chloride. Compounding with NaGP and calcium chloride allows the practitioner a mechanism for reducing the aluminum load in PN.

Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution.

A sensitive and specific reversed-phase high-performance liquid chromatographic method with ultraviolet detection was developed for the determination of vitamin C, using tetrabutylammonium hydroxide as an ion-pair reagent in a compound oral solution containing 100 mg/mL calcium gluconate and 1.25 mg/mL vitamin C. The aqueous phase contained 0.005 mol/L tetrabutylammonium hydroxide and the mobile phase consisted of a mixture of the aqueous phase-methanol (80:20, v/v, pH 6.0 adjusted by phosphoric acid). The linearity, sensitivity and specificity, accuracy, and stability of the procedure were evaluated. The calibration curves for vitamin C were linear in the range of 10.0-100.0 µg/mL. The percentage coefficient of variation of the quantitative analysis of the vitamin C in the products analysis was within 5%. The method was successfully applied to determine the stability of vitamin C in the compound oral solution. It was found that the vitamin C peak was symmetrical and the column efficiency was high. The method is simple and suitable for stability testing of a low concentration of vitamin C preparation.

Effects of elevated calcium on motor and exploratory activities of rats.

The effects of serum and brain calcium concentration on rat behavior were tested by maintaining animals on either distilled water (N = 60) or water containing 1% calcium gluconate (N = 60) for 3 days. Animals that were maintained on high calcium drinking water presented increased serum calcium levels (control = 10.12 +/- 0.46 vs calcium treated = 11.62 +/- 0.51 microg/dl). Increase of brain calcium levels was not statistically significant. In the behavioral experiments each rat was used for only one test. Rats that were maintained on high calcium drinking water showed increased open-field behavior of ambulation (20.68%) and rearing (64.57%). On the hole-board, calcium-supplemented animals showed increased head-dip (67%) and head-dipping (126%), suggesting increased ambulatory and exploratory behavior. The time of social interaction was normal in animals maintained on drinking water containing added calcium. Rats supplemented with calcium and submitted to elevated plus-maze tests showed a normal status of anxiety and elevated locomotor activity. We conclude that elevated levels of calcium enhance motor and exploratory behavior of rats without inducing other behavioral alterations. These data suggest the need for a more detailed analysis of several current proposals for the use of calcium therapy in humans, for example in altered blood pressure states, bone mineral metabolism disorders in the elderly, hypocalcemic states, and athletic activities.

Preoperative localization of pancreatic insulinoma by selective intraarterial calcium injection and hepatic venous sampling.

Preoperative localization of insulinomas is desirable by most surgeons. Imaging with ultrasonography, computed tomography, magnetic resonance imaging, nuclear medicine and angiography may fail to demonstrate these small tumors in up to 10%, while a smaller percentage may be missed even after careful surgical exploration and intraoperative ultrasonography. Selective intraarterial injection of calcium with hepatic venous sampling has been reported to be a very accurate technique for preoperative localization of insulinomas. We report such a case where the clinical symptoms were highly suggestive but imaging algorithm failed to reveal any lesion and we review the literature.

Manejo terapéutico de la hiperpotasemia aguda / Management of acute hyperkalemia in children

La hiperpotasemia es un hallazgo común en la práctica pediátrica hospitalaria. Representa una urgencia vital con riesgo de complicaciones cardíacas, por lo que su reconocimiento y tratamiento inmediato son esenciales. En este trabajo proponemos un protocolo para la evaluación y tratamiento de la hipercaliemia aguda en el niño. Además, hacemos una relación de las diferentes estrategias terapéuticas utilizadas en el manejo de este trastorno (AU)

Aluminum in parenteral nutrition solution--sources and possible alternatives.

The extent of aluminum (Al) contamination in parenteral nutrition (PN) solutions for infants is not known. Aluminum was measured in 136 samples from various commercially available components that are used with PN. Results showed Al content varied widely among different components. The same chemical may have a different Al content depending on the manufacturer. However, Al contents were similar among lots from the same manufacturer for the same chemical. Aluminum contamination was arbitrarily classified as high (greater than 500 micrograms Al/liter), intermediate (51-500 micrograms Al/liter) or low (less than or equal to 50 micrograms Al/liter). The high group included most calcium and phosphorus containing salts, 1 multivitamin preparation, folic acid, ascorbic acid and concentrated (25%) albumin. The intermediate group included sodium lactate, potassium phosphates, zinc and chromium chloride, multitrace metal preparation, and 5% plasma protein. The low group included amino acids, sterile water and dextrose water, chloride salts of sodium, potassium, calcium, copper and chromium, sodium phosphates, magnesium sulphate, zinc sulphate, vitamin B12, vitamin K1, 1 multivitamin preparation, soybean oil emulsion and heparinized (2 U/ml) saline. PN solutions made from high Al components may contain up to 300 micrograms Al/liter. Calcium gluconate contributed greater than 80% of the total Al load from PN. Lowering of Al content in calcium gluconate in addition to use of specific low Al components offers the opportunity to significantly lower the Al concentration of the final PN solution and theoretically may achieve an Al content as low as 12 micrograms/l.(ABSTRACT TRUNCATED AT 250 WORDS)

Assay of calcium borogluconate veterinary medicines for calcium gluconate, boric acid, phosphorus, and magnesium by using inductively coupled plasma emission spectrometry.

An inductively coupled plasma spectrometric method is described for the determination of 4 elements (Ca, B, P, and Mg) in calcium borogluconate veterinary medicines. Samples are diluted, acidified, and sprayed directly into the plasma. Reproducibility relative confidence intervals for a single sample assay are +/- 1.4% (calcium), +/- 1.8% (boron), +/- 2.6% (phosphorus), and +/- 1.4% (magnesium). The total element concentrations for each of 4 elements compared favorably with concentrations determined by alternative methods. Formulation estimates of levels of calcium gluconate, boric acid, phosphorus, and magnesium salts can be made from the analytical data.

The adverse effects of high oral osmolal mixtures in neonates. A review and a study of the osmolality of calcium preparations.

In both animals and humans, there are numerous clinical, physiologic, and morphologic alterations that occur when hypertonic solutions are introduced into the alimentary tract. The most serious adverse effect observed in the human infant is necrotizing enterocolitis. A short in vitro study analyzing osmolalities of drug-formula mixtures at various dilutions, conducted by the authors, showed that an unacceptable degree of high osmolality may be achieved in the preparation of common medications used in newborn nurseries. Although review of the literature confirms that, in general, the osmolalities of mixtures fed to newborns should not exceed 460 mOsm/kg H2O, lower levels would be preferable in ill and low birth weight newborns. When possible, consideration should be given to the use of parenteral medication for the critically ill neonate. Ideally, the osmolalities of mixtures fed to newborns should be measured if they are not known or cannot be calculated.

Determination of calcium gluconate by selective oxidation with periodate.

A modified analytical method was developed which can accurately quantitate calcium gluconate and its pharmaceutical preparations in the presence of other calcium compounds or other cations able to complex with EDTA. The proposed method was based on the principle of the Malaprade reaction, according to which gluconic acid is selectively and quantitatively oxidized by sodium periodate. The content of calcium gluconate was calculated from the amount of gluconic acid found. The selective oxidation proceeded at 50 degrees C for 10 min, yielding approximately 100% recovery of calcium gluconate. The proposed method was accurate, precise, and superior to the compendia EDTA- complexometric method in terms of specificity.